Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Summary of the proceedings from the 10th annual meeting of molecularly targeted therapy in non-small cell lung cancer.

Literature DB >> 21102234

Summary of the proceedings from the 10th annual meeting of molecularly targeted therapy in non-small cell lung cancer.

Ramaswamy Govindan¹.

Abstract

Entities: Chemical Disease Gene Mutation Species

Mesh：

Substances：

Year: 2010 PMID： 21102234 PMCID： PMC3203685 DOI： 10.1097/JTO.0b013e3181fd6fe1

Source DB: PubMed Journal: J Thorac Oncol ISSN： 1556-0864 Impact factor: 15.609

× No keyword cloud information.

9 in total

1. Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis.

Authors: Jian-Min Tang; Quan-Ying He; Rui-Xia Guo; Xiu-Jun Chang
Journal: Lung Cancer Date: 2006-02 Impact factor: 5.705

2. Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors.

Authors: Junji Tsurutani; Junya Fukuoka; Hiroko Tsurutani; Joanna H Shih; Stephen M Hewitt; William D Travis; Jin Jen; Phillip A Dennis
Journal: J Clin Oncol Date: 2005-12-05 Impact factor: 44.544

3. BRG1, a component of the SWI-SNF complex, is mutated in multiple human tumor cell lines.

Authors: A K Wong; F Shanahan; Y Chen; L Lian; P Ha; K Hendricks; S Ghaffari; D Iliev; B Penn; A M Woodland; R Smith; G Salada; A Carillo; K Laity; J Gupte; B Swedlund; S V Tavtigian; D H Teng; E Lees
Journal: Cancer Res Date: 2000-11-01 Impact factor: 12.701

4. Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer.

Authors: Daniel T Milton; Gregory J Riely; Christopher G Azzoli; Jorge E Gomez; Robert T Heelan; Mark G Kris; Lee M Krug; William Pao; Barbara Pizzo; Naiyer A Rizvi; Vincent A Miller
Journal: Cancer Date: 2007-08-01 Impact factor: 6.860

5. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.

Authors: Shi-Yong Sun; Laura M Rosenberg; Xuerong Wang; Zhongmei Zhou; Ping Yue; Haian Fu; Fadlo R Khuri
Journal: Cancer Res Date: 2005-08-15 Impact factor: 12.701

6. Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions.

Authors: Binaifer R Balsara; Jianming Pei; Yasuhiro Mitsuuchi; Robert Page; Andres Klein-Szanto; Hao Wang; Michael Unger; Joseph R Testa
Journal: Carcinogenesis Date: 2004-07-07 Impact factor: 4.944

7. Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung.

Authors: Montserrat Sanchez-Cespedes; Paola Parrella; Manel Esteller; Shuji Nomoto; Barry Trink; James M Engles; William H Westra; James G Herman; David Sidransky
Journal: Cancer Res Date: 2002-07-01 Impact factor: 12.701

8. Tobacco carcinogen-induced cellular transformation increases activation of the phosphatidylinositol 3'-kinase/Akt pathway in vitro and in vivo.

Authors: Kip A West; Ilona R Linnoila; Steven A Belinsky; Curtis C Harris; Phillip A Dennis
Journal: Cancer Res Date: 2004-01-15 Impact factor: 12.701

9. Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition.

Authors: Alexandra C Racanelli; Scott B Rothbart; Cortney L Heyer; Richard G Moran
Journal: Cancer Res Date: 2009-06-23 Impact factor: 12.701